Medipost announced Wednesday that it acquired patents in six European countries based on its core technology of Alzheimer's disease treatment.
The patent relates to a pharmaceutical composition for treating neuropathy using “Cell Adhesion Molecule (ICAM) -1,” a protein involved in adhesion and migration of inflammatory cells, it said
|Medipost has acquired six patents in Europe for the treatment of neurological diseases.|
The name of the patent is “the use of ICAM-1 for the prevention or treatment of neurological diseases,” and Medipost acquired it in the U.K., Germany, France, Italy, Spain, and Switzerland at the same time.
ICAM-1 can be secreted when a cord blood-derived stem cell is administered to a patient who has Alzheimer's disease, and it functions to induce the degradation of amyloid beta plaque, which is known as a causative agent of dementia.
"The patented technology is used in the most important process in the treatment of dementia, and it is also applied to Neurostem, a drug for Alzheimer's,” a company official said.
Medipost 메디포스트 (CEO: Yang Yoon-sun양윤선) has already acquired patents for the treatment of neurological diseases using ICAM-1 in Korea, U.S. Canada, Australia, China, and Japan.
<© Korea Biomedical Review, All rights reserved.>